Preferred Label : Anti-TNFR2 Monoclonal Antibody NBL-020;
NCIt definition : A fully human monoclonal antibody directed against tumor necrosis factor receptor
2 (TNFR2; tumor necrosis factor receptor superfamily member 1B; TNFRSF1B), with potential
immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon
administration, anti-TNFR2 monoclonal antibody NBL-020 targets and binds to TNFR2
expressed on immune suppressive cells, such as tumor-associated regulatory T-cells
(Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment
(TME). This prevents the activation of TNFR2 by endogenous tumor necrosis factor (TNF),
inhibits TNFR2-mediated signaling, and blocks the activation of the nuclear factor
kappa B (NF-kB) signaling pathway, which halts TNFR2-mediated immunosuppression, inhibits
the proliferation and function of Tregs, induces and expands intra-tumoral CD8 T-cells,
and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. TNFR2
plays a role in tumor necrosis factor signaling, tumor expansion and survival.;
Molecule name : NBL-020; NBL 020;
Origin ID : C200807;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
